Evidence map›Paper›PMID 19402887›Full record

ArticleRespiratory research2009

Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury.

Yvonne P de Visser, Frans J Walther, El Houari Laghmani, Hester Boersma, Arnoud van der Laarse, Gerry Tm Wagenaar

Open access · goldAbstract read
In one paragraph

Article in Respiratory research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 122 citations in OpenAlex.

  1. Trial
  2. Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2015
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. New Pharmacologic Approaches to Bronchopulmonary Dysplasia.Journal of experimental pharmacology · 2021
    Review
  19. Review
  20. Interactive and independent effects of early lipopolysaccharide and hyperoxia exposure on developing murine lungs.American journal of physiology. Lung cellular and molecular physiology · 2020
    Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Yvonne P de VisserDepartment of Pediatrics, Division of Neonatology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands. y.p.de_visser@lumc.nl
Frans J Walther
El Houari Laghmani
Hester Boersma
Arnoud van der Laarse
Gerry Tm Wagenaar
Leiden University Medical Center · NL

Funding

Synthetic Lung Surfactant Optimized for Biomedical ApplicationR01HL092158 · NHLBI · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI WALTHER, FRANCISKUS JOHANNES · 2008 to 2011
$1.3M
Synthetic surfactant and toxic chemical lung injuryR01ES015330 · NIEHS · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI WALTHER, FRANCISKUS JOHANNES · 2008 to 2011
$1.2M
NHLBI NIH HHS 1R01 HL092158NHLBI NIH HHS R01 HL092158NIEHS NIH HHS R01 ES015330
6 · The paper itself

Abstract

backgroundPhosphodiesterase-5 inhibition with sildenafil has been used to treat severe pulmonary hypertension and bronchopulmonary dysplasia (BPD), a chronic lung disease in very preterm infants who were mechanically ventilated for respiratory distress syndrome.

methodsSildenafil treatment was investigated in 2 models of experimental BPD: a lethal neonatal model, in which rat pups were continuously exposed to hyperoxia and treated daily with sildenafil (50-150 mg/kg body weight/day; injected subcutaneously) and a neonatal lung injury-recovery model in which rat pups were exposed to hyperoxia for 9 days, followed by 9 days of recovery in room air and started sildenafil treatment on day 6 of hyperoxia exposure. Parameters investigated include survival, histopathology, fibrin deposition, alveolar vascular leakage, right ventricular hypertrophy, and differential mRNA expression in lung and heart tissue.

resultsProphylactic treatment with an optimal dose of sildenafil (2 x 50 mg/kg/day) significantly increased lung cGMP levels, prolonged median survival, reduced fibrin deposition, total protein content in bronchoalveolar lavage fluid, inflammation and septum thickness. Treatment with sildenafil partially corrected the differential mRNA expression of amphiregulin, plasminogen activator inhibitor-1, fibroblast growth factor receptor-4 and vascular endothelial growth factor receptor-2 in the lung and of brain and c-type natriuretic peptides and the natriuretic peptide receptors NPR-A, -B, and -C in the right ventricle. In the lethal and injury-recovery model we demonstrated improved alveolarization and angiogenesis by attenuating mean linear intercept and arteriolar wall thickness and increasing pulmonary blood vessel density, and right ventricular hypertrophy (RVH).

conclusionSildenafil treatment, started simultaneously with exposure to hyperoxia after birth, prolongs survival, increases pulmonary cGMP levels, reduces the pulmonary inflammatory response, fibrin deposition and RVH, and stimulates alveolarization. Initiation of sildenafil treatment after hyperoxic lung injury and continued during room air recovery improves alveolarization and restores pulmonary angiogenesis and RVH in experimental BPD.

Indexed as

Disease Models, AnimalAnimalsAnimals, NewbornFibrinHumansHyperoxiaHypertrophy, Right VentricularLung InjuryPhosphodiesterase InhibitorsPiperazinesPneumoniaPurinesRatsRats, WistarSildenafil CitrateSulfonesFibrinPhosphodiesterase InhibitorsPiperazinesPurinesSildenafil CitrateSulfones

Identifiers

PMID19402887
PMCPMC2681457
OpenAlexW2030123520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.